Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 201–300 of 1,003
Food, physiology and drug delivery
Varum, F., Hatton, G. B., & Basit, A. W. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.034 · Cited by 131
Cherniakov, I., Izgelov, D., Domb, A. J., & Hoffman, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.003 · Cited by 131
“Intestinal absorption and bioavailability following oral drug administration is dictated by several factors such as drug solubility in the gastro-intestinal (GI) milieu, permeability of the drug through the enterocyte membrane, activity of efflux transporters and metabolizing enzymes (Porter et al., 2007).”
BackgroundSolidification to improve the biopharmaceutical performance of SEDDS: Opportunities and challenges
Joyce, P. M., Dening, T. J., Meola, T. R., Schultz, H. B., Holm, R., Thomas, N., & Prestidge, C. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.11.006 · Cited by 131
“LBDDS enhance drug solubilisation during gastrointestinal (GI) processing by creating a lipophilic microenvironment that restricts drug precipitation, while concurrently facilitating drug transport towards intestinal absorption sites [1-3].”
BackgroundHu, X., Zhang, J., Yu, Z., Xie, Y., He, H., Qi, J., Dong, X., Lü, Y., Zhao, W., & Wu, W. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.06.013 · Cited by 131
Preparation and Comparative Release Characteristics of Three Anthocyanin Encapsulation Systems
Oidtmann, J., Schantz, M., Mäder, K., Baum, M., Berg, S., Betz, M., Kulozik, U., Leick, S., Rehage, H., Schwarz, K., et al. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf2047515 · Cited by 131
McClements, D. J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.46 · Cited by 131
Sun, M., Zhai, X., Xue, K., Hu, L., Yang, X., Gao, L., & Si, L. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.04.011 · Cited by 131
Mechanisms of chylomicron uptake into lacteals
Dixon, J. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05716.x · Cited by 112
Aboalnaja, K. O., Yaghmoor, S., Kumosani, T., & McClements, D. J. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1162154 · Cited by 130
Kesharwani, R., Jaiswal, P. K., Patel, D. K., & Yadav, P. K. (2022) · Biomedical Materials & Devices · doi:10.1007/s44174-022-00041-0 · Cited by 130
“…different colloidal particles with bile components, they can ultimately retain a huge amount of lipophilic medicament in solution using micellar solubilization [35–37]. the ultimate goal of any oral lipid-based formulation is effective medication absorption by the intestinal mucosal cells.”
The effect of surface charge on oral absorption of polymeric nanoparticles
Du, X., Wang, J., Iqbal, S., Li, H., Cao, Z., Wang, Y., Du, J., & Wang, J. (2018) · Biomaterials Science · doi:10.1039/c7bm01096f · Cited by 129
Singh, A., Neupane, Y. R., Mangla, B., & Kohli, K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.06.003 · Cited by 129
Siew, A., Le, H., Thiovolet, M., Gellert, P., Schätzlein, A. G., & Uchegbu, I. F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200469a · Cited by 130
Li, Y., Hu, M., Xiao, H., Du, Y., Decker, E. A., & McClements, D. J. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.004 · Cited by 128
Chime, S. A. (2013) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajppx2013.0004 · Cited by 128
Rao, S., & Prestidge, C. A. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1151872 · Cited by 128
Low Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion
Kossena, G. A., Charman, W. N., WILSON, C. G., O’Mahony, B., Lindsay, B., Hempenstall, J., Davison, C. L., Crowley, P., & Porter, C. J. H. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9363-8 · Cited by 128
“In recent years increasing numbers of studies have described the utility of lipid based formulations as a means to enhance the absorption of poorly water-soluble drugs ( 39 ).”
BackgroundSelf-citationRao, J., Decker, E. A., Xiao, H., & McClements, D. J. (2013) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6215 · Cited by 127
Zhang, Z., Niu, B., Chen, J., He, X., Bao, X., Zhu, J., Yu, H., & Li, Y. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.024 · Cited by 127
“After oral administration, the lipophilic drugs had to be first dissolved in the GI fluids and then absorbed across the intestinal enterocytes [30].”
BackgroundCurrent Status of Supersaturable Self-Emulsifying Drug Delivery Systems
Park, H., Ha, E., & Kim, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040365 · Cited by 127
“Thus, the hydrophobic and poorly water-soluble drugs that are incorporated in SEDDSs with lipids can also be solubilized by the formation of mixed micellar bile salt-lipid complexes, such as colloidal vesicles, after lipid digestion [21].”
BackgroundWhat is modulating solubility in simulated intestinal fluids?
Ottaviani, G., Gosling, D. J., Patissier, C., Rodde, S., Zhou, L., & Faller, B. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.07.012 · Cited by 126
Mehrad, B., Ravanfar, R., Licker, J., Regenstein, J. M., & Abbaspourrad, A. (2017) · Food Research International · doi:10.1016/j.foodres.2017.12.036 · Cited by 126
Wang, D., Yu, C., Xu, L., Shi, L., Tong, G., Wu, J., Liu, H. S., Yan, D., & Zhu, X. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04556 · Cited by 126
Lipid-based emulsion drug delivery systems — a comprehensive review
Dhaval, M., Vaghela, P., Patel, K., Sojitra, K., Patel, M., Patel, S., Dudhat, K. R., Shah, S. R., Manek, R. A., & Parmar, R. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01071-9 · Cited by 126
Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge
Janga, K. Y., Jukanti, R., Velpula, A., Sunkavalli, S., Bandari, S., Kandadi, P., & Veerareddy, P. R. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.010 · Cited by 126
Critical steps and energetics involved in a successful development of a stable nanoemulsion
Qadir, A., Faiyazuddin, M., Hussain, T., Alshammari, T. M., & Shakeel, F. (2015) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2015.11.050 · Cited by 124
Neupane, Y. R., Srivastava, M., Ahmad, N., Kumar, N., Bhatnagar, A., & Kohli, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.001 · Cited by 124
“It has reported that lipid protects drug from acidic degradation, increases intestinal permeability, promotes oral absorption through lymphatic transport by reducing first pass metabolism and higher amount of drug loading which enhances the availabile of drug to the systemic circulation (Xie et al., 2011; Pouton, 2006…”
BackgroundRen, T., Wang, Q., Xu, Y., Cong, L., Gou, J., Tao, X., Zhang, Y. X., He, H., Yin, T., Zhang, H., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.015 · Cited by 123
“Lipids, as conventional and biocompatible excipients, have a special capacity for increasing the drug loading and encapsulation efficiency, maintaining drugs in a solubilized state and enhancing the drug stability against complex environments, particularly for lipophilic, poorly permeable, unstable, small molecule dru…”
BackgroundDrug-excipient behavior in polymeric amorphous solid dispersions
Teja, S. B., Patil, S. P., Shete, G., Patel, S., & Bansal, A. K. (2016) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.1048 · Cited by 123
Singh, B., Khurana, L. K., Bandyopadhyay, S., Kapil, R., & Katare, O. P. (2011) · Drug Delivery · doi:10.3109/10717544.2011.604686 · Cited by 123
“All the formulations, prepared as per the experimental design, exhibited nano globule size ranging between 46–475 nm, which is considered ideal for a low emulsification time and enhanced micellar absorption (Porter et al., 2007; Nielsen et al., 2008).”
BackgroundPharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations
Kollipara, S., & Gandhi, R. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.09.001 · Cited by 122
Charge‐Reversible Nanoparticles: Advanced Delivery Systems for Therapy and Diagnosis
Veider, F., Armengol, E. S., & Bernkop‐Schnürch, A. (2023) · Small · doi:10.1002/smll.202304713 · Cited by 124
Alfutaimani, A. S., Alharbi, N. K., Alahmari, A. S., Alqabbani, A. A., & Aldayel, A. M. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100305 · Cited by 122
Wang, Q., Wei, Q., Yang, Q., Cao, X., Li, Q., Shi, F., Tong, S. S., Feng, C., Yu, Q., Yu, J., et al. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.006 · Cited by 121
Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs
Mohite, P. B., Singh, S. K., Pawar, A. R., Sangale, A., & Prajapati, B. G. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1232012 · Cited by 121
“…with bile components, which eventually enables them to use micellar solubilization to keep a sizable amount of lipophilic medication in solution (Porter et al., 2007)., the procedures for lipid-based medication formulations start with dispersion to form lipid or emulsion droplets, and bile…”
Wang, H., Pastorin, G., & Lee, C. (2016) · Advanced Science · doi:10.1002/advs.201500441 · Cited by 121
Basic principles of drug delivery systems – the case of paclitaxel
Ezrahi, S., Aserin, A., & Garti, N. (2018) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2018.11.004 · Cited by 121
Intravital imaging of intestinal lacteals unveils lipid drainage through contractility
Choe, K., Jang, J. Y., Park, I., Kim, Y., Ahn, S., Park, D.-Y., Hong, Y.-K., Alitalo, K., Koh, G. Y., & Kim, P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76509 · Cited by 117
Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery
Hu, X., Fan, W., Yu, Z., Lü, Y., Qi, J., Zhang, J., Dong, X., Zhao, W., & Wu, W. (2015) · Nanoscale · doi:10.1039/c5nr07474f · Cited by 120
Zou, L., Zheng, B., Zhang, R., Zhang, Z., Liu, W., Liu, C., Xiao, H., & McClements, D. J. (2015) · RSC Advances · doi:10.1039/c5ra22834d · Cited by 120
Vithani, K., Goyanes, Á., Jannin, V., Basit, A. W., Gaisford, S., & Boyd, B. J. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2639-y · Cited by 119
Characterising Lipid Lipolysis and Its Implication in Lipid-Based Formulation Development
Thomas, N., Holm, R., Rades, T., & Müllertz, A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9398-6 · Cited by 119
“crystalline and ‘viscous isotropic’ phases (15,22,23).”
Koziolek, M., Garbacz, G., Neumann, M., & Weitschies, W. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300604u · Cited by 119
Fuchs, A., & Dressman, J. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24183 · Cited by 118
Singh, A., Neupane, Y. R., Panda, B. P., & Kohli, K. (2017) · Journal of Microencapsulation · doi:10.1080/02652048.2017.1340355 · Cited by 118
“The interaction between transport processes by lymphatic medication through intestine and by enterocytes-based transport also plays a major role for the drug absorption (Porter et al., 2007).”
BackgroundChallenges and Opportunities in the Delivery of Cancer Therapeutics: Update on Recent Progress
Lorscheider, M., Gaudin, A., Nakhlé, J., Veiman, K.-L., Richard, J., & Chassaing, C. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0079 · Cited by 119
Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery
Hallan, S. S., Kaur, P., Kaur, V., Mishra, N., & Vaidya, B. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.951721 · Cited by 117
“Therefore, the molecules can effectively solubilize in the lipophilic microenvironment developed by the presence of fat and their corresponding digested fatty acid products mixed with endogenous micellar components (Mu et al. 2013, Porter et al. 2007).”
BackgroundMcClements, D. J., Salvia‐Trujillo, L., Zhang, R., Zhang, Z., Zou, L., Yao, M., & Xiao, H. (2015) · Food Research International · doi:10.1016/j.foodres.2015.11.017 · Cited by 117
Intestinal fatty acid binding protein: A rising therapeutic target in lipid metabolism
Huang, X. X., Zhou, Y., Sun, Y., & Wang, Q. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101178 · Cited by 116
Solvent-Free Melting Techniques for the Preparation of Lipid-Based Solid Oral Formulations
Becker, K., Salar-Behzadi, S., & Zimmer, A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1661-y · Cited by 115
Li, Y., & McClements, D. J. (2010) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2010.09.024 · Cited by 115
Self emulsifying drug delivery system for enhanced solubility and dissolution of glipizide
Agrawal, A. G., Kumar, A., & Gide, P. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.11.022 · Cited by 115
Liposomal delivery systems for intestinal lymphatic drug transport
Ahn, H., & Park, J. (2016) · Biomaterials Research · doi:10.1186/s40824-016-0083-1 · Cited by 115
“Thus, these unsaturated and longer-chain fatty acids are assembled into larger lipoprotein chylomicrons and enter the intestinal lymphatic pathway [3, 8].”
BackgroundInfluentialDesign and Evaluation of Self-Nanoemulsifying Drug Delivery System of Flutamide
Jyothi, B. J., & Sreelakshmi, K. (2011) · Journal of Young Pharmacists · doi:10.4103/0975-1483.76413 · Cited by 114
“[6] Although the exact mechanisms responsible for this enhanced absorption are not fully known, it is believed that factors including improved drug solubilization, increased membrane permeability, and lymphatic transport may make significant contributions.[7,8]”
BackgroundWilliams, H. D., Sassene, P. J., Kleberg, K., Calderone, M., Igonin, A., Jule, E., Vertommen, J., Blundell, R., Benameur, H., Müllertz, A., et al. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1038-z · Cited by 113
Self-citationVithani, K., Jannin, V., Pouton, C. W., & Boyd, B. J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.008 · Cited by 113
Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route
Mahor, A., Singh, P. P., Gupta, R., Bhardwaj, P., Rathore, P., Kishore, A., Goyal, R., Sharma, N., Verma, J., Rosenholm, J. M., et al. (2023) · Journal of Nanotechnology · doi:10.1155/2023/4687959 · Cited by 113
Larsen, A. T., Holm, R., Pedersen, M. L., & Müllertz, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9641-0 · Cited by 113
“There are many different ways to conduct in vitro lipolysis: (1) calcium can be added at the beginning as a bolus or continuous during the experiment, (2) the level of bile salt can be altered, (3) the amount of formulation added to the model can be varied, (4) the amount of lipase added can be varied, and (5) the len…”
The gastrointestinal stability of lipid nanocapsules
Roger, E., Lagarce, F., & Benoît, J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.069 · Cited by 113
Gonçalves, L., Maestrelli, F., Mannelli, L. D. C., Ghelardini, C., Almeida, A. J., & Mura, P. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.02.012 · Cited by 112
“Among these, one of the most accepted is that SLN can facilitate the oral absorption of poorly-water soluble drugs by maintaining a solubilized state of the drugs in the GI tract, and by facilitating the formation of mixed micelles, promoting secretion of endogenous phospholipids and bile salts [32,39].”
BackgroundNanoemulsions: An emerging platform for increasing the efficacy of nutraceuticals in foods
Zhang, R., Zhang, Z., & McClements, D. J. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111202 · Cited by 112
Shao, B., Cui, C., Ji, H., Tang, J., Wang, Z., Liu, H., Qin, M., Li, X., & Wu, L. (2014) · Drug Delivery · doi:10.3109/10717544.2014.898109 · Cited by 112
“In present study, the SEDDS formulation had the smaller emulsion droplet, the faster drug release and the higher permeability in intestine, which could enhance the quantity of the absorption for piperine once again into the intestine (Porter et al., 2007).”
BackgroundHu, X., Chen, L., Chen, D., Zhang, J., Liu, Z., Wu, W., & Hong-tao, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.055 · Cited by 112
Biorelevant Dissolution Media Simulating the Proximal Human Gastrointestinal Tract: An Update
Jantratid, E., & Dressman, J. (2009) · Dissolution Technologies · doi:10.14227/dt160309p21 · Cited by 112
“Moreover, the previous versions of the biorelevant media do not reflect the lipolysis products of meal digestion that are known to enhance the solubility and dissolution of poorly soluble lipophilic drugs (3).”
BackgroundInfluentialBerthelsen, R., Klitgaard, M., Rades, T., & Müllertz, A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.010 · Cited by 111
The effects of excipients on transporter mediated absorption
Goole, J., Lindley, D. J., Roth, W. J., Carl, S. M., Amighi, K., Kauffmann, J., & Knipp, G. T. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.019 · Cited by 111
Simović, S., Heard, P. J., He, H. Z., Song, Y., Peddie, F., Davey, A. K., Lewis, A., Rades, T., & Prestidge, C. A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900063t · Cited by 111
Izgelov, D., Shmoeli, E., Domb, A. J., & Hoffman, A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119201 · Cited by 110
Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo
Chu, C., Tong, S., Xu, Y. D., Wang, L., Fu, M., Ge, Y., Yu, J., & Xu, X. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.25 · Cited by 110
Li, F., Hu, R., Wang, B., Gui, Y., Cheng, G., Gao, S., Ye, L., & Tang, J. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.02.002 · Cited by 109
Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs
Beloqui, A., del Pozo‐Rodríguez, A., Isla, A., Rodríguez‐Gascón, A., & Solinís, M. Á. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.06.013 · Cited by 109
Mitra, A., & Kesisoglou, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400256h · Cited by 108
Liu, Y., Wang, L., Zhao, Y., He, M., Zhang, X., Niu, M., & Feng, N. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.09.052 · Cited by 108
“After NLC or ME is located within the GI tract, the fate of the loaded drugs is of first essential for efficient absorption, which are determined by the dispersion process and subsequent digestion process (Devraj et al., 2013; Porter et al., 2007).”
BackgroundMontelukast-loaded nanostructured lipid carriers: Part I Oral bioavailability improvement
Patil-Gadhe, A., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.019 · Cited by 107
Sander, C., & Holm, P. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9340-0 · Cited by 107
“Lipid-based formulation systems have become increasingly important in the formulation of lipophilic drug substances as they can facilitate the dispersion of a drug in the gastrointestinal tract resulting in enhanced oral bioavailability ( 4 ).”
BackgroundBSA-dextran emulsion for protection and oral delivery of curcumin
Wang, C., Liu, Z., Xu, G., Yin, B., & Yao, P. (2016) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2016.04.037 · Cited by 107
Tan, M.-E., He, C.-H., Jiang, W., Zeng, C., Yu, N., Huang, W., Gao, Z., & Xing, J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131893 · Cited by 107
Overcoming poor permeability: translating permeation enhancers for oral peptide delivery
Maher, S., & Brayden, D. J. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.11.006 · Cited by 107
Warren, D. B., Anby, M. U., Hawley, A. M., & Boyd, B. J. (2011) · Langmuir · doi:10.1021/la2011937 · Cited by 107
Uppal, S., Italiya, K. S., Chitkara, D., & Mittal, A. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.09.049 · Cited by 106
Perrigue, P. M., Murray, R. A., Mielcarek, A., Henschke, A., & Moya, S. E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060770 · Cited by 107
“The most common materials employed in the manufacture of NCs are polymers [9], lipids [10,11], and metals [12].”
BackgroundMaio, S. D., & Carrier, R. L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.034 · Cited by 106
Fattahi, N., Shahbazi, M., Maleki, A., Hamidi, M., Ramazani, A., & Santos, H. A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.012 · Cited by 105
Li, Y., & McClements, D. J. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.03.019 · Cited by 105
Recent Advances in Self-Emulsifying Drug Delivery Systems (SEDDS)
Singh, B., Beg, S., Khurana, R. K., Sandhu, P. S., Kaur, R., & Katare, O. P. (2014) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2014008502 · Cited by 104
Wu, W. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s8311 · Cited by 104
“Most importantly, lipid-based drug delivery systems are able to transform into important secondary vehicles (mixed micelles, cubic and hexagonal nanoparticles, vesicular carriers) in the GI and are believed to facilitate absorption of lipids and poorly water-soluble drugs.(22) Cubic nanoparticles (cubosomes) are dispe…”
Rizwanullah, M., Amin, S., & Ahmad, J. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1191080 · Cited by 104
“Oral route is the most preferred and convenient route for the administration of drug formulations but lipophilic drugs do not offer high systemic exposure due to their poor aqueous solubility [8,9].”
BackgroundXu, G., Wang, C., & Yao, P. (2017) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2017.05.010 · Cited by 103
“It was reported that emulsions are able to generate mixed micelles that increase the bioaccessibility of the loaded compounds after oral administration and digestion (Porter et al., 2007; Yu & Huang, 2012).”
BackgroundIntestinal absorption of insulin nanoparticles: Contribution of M cells
Lopes, M., Abrahim, B. A., Cabral, L. M., Rodrigues, C. R., Seiça, R. M. F., Veiga, F., & Ribeiro, A. J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.02.014 · Cited by 103
Investigation of the Absorption Mechanism of Solubilized Curcumin Using Caco-2 Cell Monolayers
Yu, H., & Huang, Q. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf201451m · Cited by 103
da Silva, H. D. M., Poejo, J., Pinheiro, A. C., Donsì, F., Serra, T., Duarte, C. M. M., Ferrari, G., Cerqueira, M. Â., & Vicente, A. A. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.08.002 · Cited by 102
Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics
Marković, M., Ben‐Shabat, S., Aponick, A. A., Zimmermann, E. M., & Dahan, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093248 · Cited by 102
“Lipi s can also stimulate intestinal lymphatic drug transport, in which the drugs c n bypass th first-pass hepatic metabolism and go directly to the systemic circulation [11].”
BackgroundAmeta, R. K., Soni, K. V., & Bhattarai, A. (2023) · Colloids and Interfaces · doi:10.3390/colloids7010016 · Cited by 102
Preparation and quality assessment of itraconazole transfersomes
Zheng, W., Fang, X.-Q., Wang, L., & Zhang, Y. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.003 · Cited by 102
Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds
Elgart, A., Cherniakov, I., Aldouby, Y., Domb, A. J., & Hoffman, A. (2012) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2012.01.007 · Cited by 102
Fatouros, D. G., & Mullertz, A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.1.65 · Cited by 85
“2 In vitro lipid digestion model In vitro lipid digestion models have recently gained a lot of attention, as a tool to understand the partitioning of the drug substance between the formed colloid phases during the digestion of lipids [28] .”
BackgroundTools for Early Prediction of Drug Loading in Lipid-Based Formulations
Alskär, L. C., Porter, C. J. H., & Bergström, C. A. S. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00704 · Cited by 94
Self-citationda Silva, H. D. M., Beldíková, E., Poejo, J., Abrunhosa, L., Serra, T., Duarte, C. M. M., Brányik, T., Cerqueira, M. Â., Pinheiro, A. C., & Vicente, A. A. (2018) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2018.09.007 · Cited by 102
Trends in small molecule drug properties: A developability molecule assessment perspective
Agarwal, P., Huckle, J. E., Newman, J., & Reid, D. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103366 · Cited by 101
The role of polymers in oral bioavailability enhancement; a review
Liu, H., Taylor, L. S., & Edgar, K. J. (2015) · Polymer · doi:10.1016/j.polymer.2015.09.026 · Cited by 101
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.